Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates (PRECONCEPTIO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02262117|
Recruitment Status : Recruiting
First Posted : October 10, 2014
Last Update Posted : December 18, 2019
|Condition or disease||Intervention/treatment||Phase|
|Reproductive Medicine||Other: standard care Drug: specific treatment||Not Applicable|
Birth rates following an embryo transfer with a mean of two embryos transferred stagnate around 23% per transfer (annual report of the Agency of Biomedicine). Some estimates that half of infertile patients treated are partially or totally concerned by problem of inadequate uterine receptivity.
The investigators' hypothesis is that a pre-conceptional immune endometrial evaluation may increase significantly birth rates since successful implantation results from both the matching of a competent embryo within a competent endometrium.
The identification of endometrial biomarkers documenting the immune uterine environment during the implantation window would be able to improve the efficacy of ART through a personalization of treatment accordingly to the ability of the patients to receive their embryos. All patients with all inclusion criteria and no exclusion criteria will be included. Only patients with a deregulation (immune analysis) will be randomized.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective, Randomized, Controlled, Two-arm Study to Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates Through a Care Personalization in Reproductive Medicine Before IVF|
|Study Start Date :||February 2015|
|Estimated Primary Completion Date :||May 2021|
|Estimated Study Completion Date :||May 2021|
Placebo Comparator: standard care
No specific treatment (standard care)
Other: standard care
No specific medical care
Experimental: specific treatment
As a deregulation has been diagnosed by immune analysis, a personalization of the medical care for this IVF/ICSI attempt will be dispensed Personalization of treatment should follow a step-to step decision tree.
Drug: specific treatment
Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
- Live birth rate (without congenital abnormality or malformation)/transfer following the first (fresh) embryo transfer after uterine immune analysis [ Time Frame: up to 15 months ]
- Ongoing pregnancy rate/transfer following the first embryo transfer at 12 weeks of amenorrhea [ Time Frame: 12 amenorrhea weeks ]
- Number of physiological pregnancies after personalization [ Time Frame: up to 15 months ]Physiological pregnancies are defined by a normal growth of the fetus and a birth at term.
- Pregnancy rate/transfer following the first embryo transfer [ Time Frame: 8 amenorrhea weeks ]
- Number of embryo implanted/number of embryos replaced) [ Time Frame: at 8, 12 and 40 amenorrhea weeks ]Implantation rate
- Number of early miscarriage in the first trimester [ Time Frame: 12 amenorrhea weeks ]
- Number of late miscarriage [ Time Frame: between 13 and 24 amenorrhea weeks ]
- Term of birth (for babies without congenital anormality or malformation) [ Time Frame: up to 15 months ]
- Weight at birth [ Time Frame: up to 15 months ]A weight of birth below the 10 percentile according to the table of reference with distribution of birth weight in function of the term of birth in the overall population define the intrauterine growth retardation (for babies without congenital anormality or malformation)
- Number of prematurity (A birth below 37 weeks of amenorrhea defines the premature birth and before 28 weeks of amenorrhea the severe preterm birth) (for babies without congenital anormality or malformation) [ Time Frame: between 28 and 37 amenorrhea weeks ]
- Number of pre-eclampsia (defined as the association of hypertension over 14/9 mm of hg with proteinuria occuring during the pregnancy- this pathology is related to insufiscient invasion during the first trimester) [ Time Frame: up to 15 months ]
- Number of pathologic pregnancy included stillbirth and congenital abnormality [ Time Frame: up to 15 months ]
- Investigate if immunologic events studying on endometrial level have an impact on blood level or are independent. [ Time Frame: up to 15 months ]Quantification by flow cytometry of circulating NK cells (CD56 +/CD16 -), T regulatory T cells (FoxP3) with study of the repretory of circulating and uterine NK receptors (NPp46, Nkp30, NKp44).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02262117
|Contact: Nathalie LEDEE, MD||06 41 67 46 email@example.com|
|Hôpital Saint-Louis - Laboratoire MatriceLAb Innove||Recruiting|
|Paris, France, 75010|
|Contact: Nathalie LEDEE, MD 06 41 67 46 25 firstname.lastname@example.org|
|Principal Investigator:||Nathalie LEDEE, MD||Assistance Publique - Hôpitaux de Paris|